Norton Rose Fulbright advises on UAE expansion of pioneering biotech company NeOnc

Global law firm Norton Rose Fulbright has advised NASDAQ-listed NeOnc Technologies Holdings, Inc. (NeOnc) on its United Arab Emirates (UAE) expansion, including the establishment of NuroMENA Holdings Ltd. (NuroMENA) in the Abu Dhabi Global Market (ADGM).

NeOnc, a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, announced the official incorporation of NuroMENA by the ADGM on 11 August 2025.

NeOnc’s UAE expansion is linked to a strategic partnership with Quazar Investment and its US$50 million cornerstone investment into NuroMENA. This investment will support the launch of NeOnc’s innovative CNS platform across the MENA region and accelerate development of its late-stage pipeline, including the NEO212 and NEO100 clinical programs.

The cross-border team was led by Dubai-based partner Jonathan Burton, with support from senior associate Michael Stevens, associate Siobhain Corr and trainee solicitor Aya Abdeen. Houston-based partner Brian Fenske also assisted.

Jonathan said:

“We are proud to have supported NeOnc on this landmark expansion into the UAE. The incorporation of NuroMENA marks a significant step forward in advancing innovative therapies for CNS cancers across the MENA region. This transaction also reflects the growing importance of the UAE as a hub for life sciences investment and cross-border clinical development.”

Amir Heshmatpour, Executive Chairman and President of NeOnc, said:

“Securing ADGM approval for NuroMENA and finalizing the US$50 million strategic partnership with Quazar Investment would not have been possible without the exceptional legal guidance and tireless dedication of the Norton Rose Fulbright team in the UAE. Their expertise, strategic counsel, and commitment to excellence have been instrumental in navigating this complex, cross-border transaction and ensuring we are positioned for long-term success.”

Norton Rose Fulbright’s global corporate, M&A and securities practice advises corporations and financial institutions across the full spectrum of industry matters, including public takeovers, private M&A, joint ventures, disposals, debt and equity capital markets, governance, general commercial and corporate advisory matters. Its lawyers work across a broad range of key industry sectors, including life sciences and healthcare; technology; financial institutions; energy, infrastructure and resources; transport; and consumer markets.